|Mr. Sizhen Wang||Co-Founder, CEO & Chairman||N/A||N/A||1977|
|Dr. Wei-Wu He Ph.D.||Co-Founder & Chairman Emeritus||N/A||N/A||1965|
|Dr. Hai Yan||Co-Founder, Chief Scientific Officer & Director||N/A||N/A||1968|
|Mr. Ce Xu||Chief Financial Officer||N/A||N/A||1982|
|Ms. Victoria Lei||Chief Operating Officer||N/A||N/A||N/A|
|Dr. Yuchen Jiao M.D., Ph.D.||Chief Technology Officer||N/A||N/A||1978|
|Mr. Yong Liang||Chief HR Officer||N/A||N/A||1974|
|Dr. Yun-Fu Hu Ph.D.||Chief Medical Officer||N/A||N/A||1963|
|Ms. Lily Liu||Chief Commercial Officer||N/A||N/A||N/A|
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.
Genetron Holdings Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.